A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: The VIA study

January 13, 2010

Combination bevacizumab and 25?J/cm2 or 12?J/cm2 PDT significantly reduced the number of bevacizumab treatments required over six months. This study aimed at examining number of treatments, but not visual acuities. However, visual acuities responded favourably in all three groups.

British Journal of Ophthalmology - To determine if reduced light dose photodynamic therapy (PDT) combined with bevacizumab will decrease the number of bevacizumab treatments required over six months compared to bevacizumab monotherapy in neovascular age-related macular degeneration (AMD).

Click here to read the full article.

Related Content:

Articles | Retina